Luis Jodar - 04 Sep 2026 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Reporting relationship: Chief Medical Officer
Issuer ticker: PCVX
Reported as of: 04 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Sep 2026, 17:40:24 UTC
Prior SEC filing: 09 Sep 2026
Source filing: View source filing
Reporting owner signature: Luis Jodar, by /s/ Peter N. Efremenko, Attorney-In-Fact

Key filing fact

Luis Jodar filed Form 4 for Vaxcyte, Inc. (PCVX) on 09 Sep 2026.

Key facts

This page summarizes Luis Jodar's Form 4 filing for Vaxcyte, Inc. (PCVX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 09 Sep 2026, 17:40.

Change

Previous filing in this sequence was filed on 09 Sep 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002151661 Primary reporting owner

Jodar Luis

Relationship: Chief Medical Officer
Address: C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, SUITE 300, SAN CARLOS
Signature: Luis Jodar, by /s/ Peter N. Efremenko, Attorney-In-Fact
Signature date: 09 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PCVX transaction

Common Stock

Award

Transaction value
Shares: +52,632
Change %
Price: $0.000000^*
Shares after: 52,632
Date: 04 Sep 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PCVX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +88,254
Change %
Price: $0.000000^*
Shares after: 88,254
Date: 04 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 88,254
Exercise price: $61.16
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 1/4 of the shares subject to the award on September 7, 2027 and 1/8 of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.

Footnote F2

1/4 of the shares subject to the option shall vest on August 31, 2027, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.